China Coronary Secondary Prevention Study
China Coronary Secondary Prevention Study (CCSPS)- Lipid-regulating
therapy with Xuezhikang for Secondary Prevention of Coronary Heart Disease
China Coronary Secondary Prevention Study Group
[Abstract]
Objective. To determine whether lipid-regulating therapy with Xuezhikang reduces the risk of coronary events and all-cause mortality in Chinese patients with coronary heart disease (CHD).
Methods. This study was a multi-centre, randomized, double blind, placebo controlled, long term follow-up clinical trial designed to compare the effect of Xuezhikang and placebo capsules. The study was conducted at 65 centers in 19 provinces in China. 4870 CHD patients, aged 18 to 75 years, with definite myocardial infarction history who had baseline cholesterol levels between 4.40 and 6.47mmol/L were recruited between May 1996 and December 2000. Patients were randomly assigned to receive treatment with Xuezhikang capsule, 0.6g Bid or matching placebo and were followed for a mean of 4 years. The primary endpoints were coronary events, including nonfatal myocardial infarction and CHD death. The secondary endpoint, analyzed by the time of first events, was all cause death. Results. Xuezhikang significantly reduced the risk of CHD events by 45.1% (P<0.0001) compared with placebo(5.72% vs 10.41%). The relative risk reduction of CHD death and nonfatal myocardial infarction was 31.0% (3.79% vs 5.49%) and 60.8% (1.93% vs.4.92%) respectively (p<0.0001). Xuezhikang resulted in a 33.0 %(P=0.0003) risk reduction in the secondary endpoint of all-cause mortality compared to placebo (5.19% vs. 7.74% ),in which there was a 54.7% (P=0.0138) risk reduction in malignancy death. Adverse effects and abnormal laboratory parameters did not differ significantly between the two groups.
Conclusion Compared with placebo, Xuezhikang can significantly decrease the incidence of nonfatal myocardial infarction and CHD death, as well as malignancy death and all-cause mortality in Chinese CHD patients.
[Key Words] Xuezhikang capsule; blood lipid; coronary heart disease; secondary prevention
-----------------------
National scientific and technological project in Chinese Ninth Five year plan.(96-906-02-10)
Correspondence to Lu Zongliang,Chinese Academy of Medical Science, Peking Union Medical Collage, Fuwai Hospital,100037,Beijing,China
China Coronary Secondary Prevention Study (CCSPS) - Lipid-regulating_英语学习_外语学习_教育专区 暂无评价 0人阅读 0次下载 举报文档 China Coronary ...
Feasibility Study of W... 18页 免费 China Coronary Seconda... 暂无评价...After secondary polymer flooding, just as shown in Table 3, fractional flow...
(二)冠心病二级预防研究 1.中国冠心病二级预防研究(China Coronary Secondary Prevention Study, CCSPS)[26-27] 目前这是我国惟一一项对冠心病二级预防的大规模,前瞻...
9. 中国冠心病二级预防研究(China coronary secondary prevention study,CCSPS): 研究表明老年患者、合并糖尿病或高血压的患者治疗后获益更显著。 特殊人群的降脂临床...
我国从1996年至2000年进 行的中国冠心病二级预防研究(China Coronary Secondary Prevention Study CCSPS)是针对中国冠心病患者进行的冠心病二级预防试验, 是一项为多...
Chapter 6 Secondary synt... 暂无评价 37页 免费 Spoofing Prevention Meth... 暂无评价 18页 免费 China Coronary Secondary... 暂无评价 11页 免费...
血脂与冠心病 ——来自中国循证医学的证据解放军总医院 叶平 CCSPS 中国冠心病二级预防研究 China Coronary Secondary Prevention Study (CCSPS) --血脂康调整血脂对...
coronary heart disease.4 In the past 20 years,...“primary prevention”, “secondary prevention”, ...study in China and it showed the lowest average...
血脂康调整血脂 对冠心病二级预防的研究 China Coronary Secondary Prevention Study (CCSPS) CCSPS) 国家九五攻关课题编号:96-906-02国家九五攻关课题编号:96-906-...
中国冠心病二级预防研究 China Coronary Secondary Prevention Study 中国老年冠心病人群唯一循证医学研究(国家九五攻关课题) 课题牵头单位:阜外心血管病医院课题协作单位:...
热门文档